Abstract
Supplementary Figure 2 (related to Fig. 2). Palbociclib in combination with OPG-Fc restrains tumor growth in vivo. A, IHC analysis of ER, HER2, p-pRb and RANK in PDX tissue, including positive cell line-derived xenograft tissue as positive control for ER and HER2, and representative images at 400X magnification. B, Single tumor growth curves (all treated animals independently of treatment completion, n = 4-5 animals, n = 8-10 tumors in the cell line-derived model, and n = 3-4 animals in the PDX model). Tumors were measured externally with a caliper at the indicated time points, and Tvol = 1/2 (length × width2) was calculated. C, Tumor weight at sacrifice (n = 6-8 tumors in the cell line-derived model, and n = 3-4 tumors in the PDX model). D, Mouse body weight during treatment (n = 3-5 animals). E, Quantification of TRAcP5b in mouse serum by ELISA (n = 2-4 samples/group). F, Venn diagram depicting the overlap between DEGs of MDA-MB-231 tumors treated with OPG-Fc (n = 2), palbociclib (Palbo, n = 2) or palbociclib + OPG-Fc (COMB, combination, n = 3) in comparison with vehicle (Veh, n = 3). The results are presented as the means ± SEMs. *p < 0.05, **p < 0.01.